Antimalarial development: a step forward in the global fight against antimicrobial resistance

Antimicrobial resistance threatens the public health response to many diseases, including malaria. R&D into new medicines is the best insurance policy against the risk of antimalarial resistance; at the same time, it is yielding promising new compounds to fight other diseases at risk of resistance. MMV has been successful at replenishing the malaria drug pipeline and bringing new medicines forward, and its strategies to fight antimalarial resistance are relevant to the effort to contain all forms of antimicrobial resistance.